Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease that is often treated with corticosteroids (CSs) [1] . A proportion of patients with RA fail to respond adequately to CS therapy [2] . RA patients can be subdivided into CS-sensitive (SS) and -resistant (SR) subgroups on the basis of the in vitro inhibition by CSs of T-cell proliferation induced by concanavalin-A (con-A), which correlates with the clinical observations [2] . The IC 50 of hydrocortisone on cell proliferation in SS subjects is 10 À6 M, whilst the value is !10 À5 M in the majority of SR patients [2] . Patients with asthma, an allergic condition associated with bronchial spasm and eosinophilic infiltration of the bronchial mucosa, have also been divided into similar subgroups that correlate with clinical responses to CS therapy [3, 4] . The underlying mechanisms involved in the SS and SR phenomenon in patients with RA remain unknown but may be related in part to the functional status of the CS receptor (CR).
We have gained more insight into the molecular basis of the anti-inflammatory actions of CS. CSs inhibit T-cell proliferation via the inhibition of interleukin (IL)-2 production and other cytokines via the CR [5] . The promoter region of the IL-2 gene contains cis-acting elements required for the maximal induction of IL-2 production that are recognized by the nuclear transcription factors AP-1, NF-B, NF-AT and OCT-1 [6, 7] . When CS binds to CR, the CS/CR complex is released from the heat shock protein 90 containing multi-protein complex, it dimerizes, transactivates and translocates to the nucleus to bind to specific DNA motifs, the glucocorticosteroid response elements (GREs) [8] . The GREs can mediate both positive and negative effects [8, 9] . The CS/CR complex also interferes with the binding of AP-1 to its site on DNA (trans-repression) [6, 7, 10] , and CSs up-regulate IB production, which sequesters NF-B in the cytoplasm [10, 11] . NF-B exists in the cytoplasm as a heterodimer (most commonly p50 and p65 subunits) bound to an inhibitor IB that exists in a number of isoforms [12] . Activation of cells by a variety of stimuli, leads to the degradation of IBs and the released NF-B then translocates to the nucleus to initiate transcription of target genes [12] [13] [14] . The binding of AP-1 and NF-B to DNA sites on target genes induces the production of pro-inflammatory cytokines such as IL-1, IL-2, IL-3, IL-6, IL-8, tumour necrosis factor (TNF) and adhesion molecules [7, 15, 16] .
CR exists in two main isoforms, CR and CR, produced by alternative splicing [17] [18] . Only CR binds to CS [18] . Other receptor isoforms such as CR-, CR-A and CR-P have been described but their functions are not fully characterized. Transfection experiments in COS-1, CV-1, HeLa S 3 and COS-7 cells by two groups of investigators showed that the CR isoform can act as a negative inhibitor of CR-mediated effects [18] [19] [20] . Bamberger et al. [19] showed that the CR isoform was able to inhibit the effects of hormone-activated human CR (CS/CR complex) on GREs in a dose dependent manner. [ 3 H]-dexamethasone binding studies indicated that the CR isoform did not alter the binding affinity of CR for CS [19] . The presence of the CR isoform in nuclear extracts and its ability to bind to radio-labelled GRE oligonucleotides suggested that its inhibitory effects were due to competition for the GRE target site [19] . Similar observations were made by Oakley et al. [20] . However, Brogan et al. using COS-7 and HEK-293 cells, showed that over-expression of the CR isoform did not interfere in a specific way with the interaction of CR with AP-1 and NF-B (transrepression) and they suggested that the effects in COS-7 cells could be due to non-specific transcriptional squelching [21] . Transfection studies in Jurkat cells showed that co-expression of CR and CR did not interfere with CR-mediated transactivation or transrepression [22] . In contrast, CR from the same plasmid preparation caused a significant inhibition of transcriptional activity in COS-7 cells, indicating a cell typespecific pattern of CR-mediated inhibition of CR-mediated CS effects [22] .
Immunohistochemistry studies in asthma patients by Leung et al. [23] have recently shown that the CR isoform is overexpressed by a significantly higher percentage of broncho-alveolar lavage airway cells from SR asthmatic patients than in SS asthmatics. Furthermore, treatment of the broncho-alveolar lavage airway cells from SR asthmatics with a combination of IL-2 and IL-4 induced a further increase in the over-expression of the CR isoform above baseline, suggesting that cytokines could induce its expression [23, 24] . This observation in SR asthmatic patients suggests a potential role of CR in the SR phenomenon seen in asthma patients. Whether a similar situation exists in RA patients who are SR has not been determined.
We have previously shown that CSs fail to inhibit IL-2 and IL-4 production by peripheral blood mononuclear cells (PBMCs) from SR RA patients [2] . This failure to inhibit IL-2 and IL-4 production in SR could potentially result in CR over-expression. It can thus be hypothesized that the over-expression of the CR isoform relative to CR could potentially contribute to a state of reduced responsiveness to CS therapy in patients with RA. We have investigated the hypothesis that the differences in the sensitivity to CS seen in patients with RA, may be a consequence, in part, of differences in the differential expression of the CR and CR. Thus, we assessed the levels of both CR and CR isoforms at mRNA and protein levels using quantitative real time polymerase chain reaction (qRT-PCR) and by immunocytofluorographic analysis of the cellular protein expression in vitrodefined SS and SR RA patients.
Methods
Patient selection. We studied a group of patients (n ¼ 22)
who were subdivided into SS (n ¼ 10) and SR (n ¼ 12) subgroups using a previously described CS sensitivity in vitro bioassay [2] . In order to control for the potential confounding effects of inflammation on CS sensitivity, only patients with similar levels of disease activity as measured by erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and number of active joints (i.e. tender and/or swollen) were selected. The demographics of these patients were not significantly different and are shown in Table 1 . All the patients fulfilled the 1987 American College of Rheumatology diagnostic criteria for RA [25] , had erosive joint disease, and had not received CS therapy within the past 3 months. All patients were on methotrexate and similar disease duration. None of the patients had another chronic inflammatory disorder other than RA. Patients with hypothalamic pituitary adrenal disorders, chronic obstructive pulmonary disease or on psychotropic drugs were excluded. Cells were isolated from each RA patient studied and then cultured; mRNA isolated from a portion of cells and cells were also immunocytofluorographically labelled for analysis of CR and CR isoforms expression. The study was approved by our local research ethics committee and all patients gave informed and written consent.
Cell preparation. Peripheral blood (20 ml) was collected into heparinized tubes for all the studies between 10:00 and 11:00 a.m. in all the subjects to avoid variations due to diurnal rhythm of hypothalamic pituitary adrenal axis activity, which could potentially affect CR expression. PBMCs were isolated by density gradient centrifugation using Lymphoprep TM (Nycomed, Oslo, Norway), washed three times in Hank's buffered saline solution and resuspended in tissue culture medium (TCM) as previously described [2] . The TCM consisted of RPMI 1640 (Life Technologies, UK) containing 10% fetal bovine serum, 100 000 IU/l penicillin and 100 mg/l streptomycin (GIBCO, Paisley, UK). Some of the resuspended cells were aliquotted and distributed equally into 1.8 ml sterile tubes, mixed with freezing medium [20% DMSO in fetal bovine serum (FBS)] 1: 1 and immediately frozen and stored in liquid nitrogen.
In vitro CS sensitivity assay. The in vitro CS sensitivity assay measured the inhibitory effect of hydrocortisone on con-A-stimulated PBMCs proliferation [2] . PBMCs (1 Â 10 5 cells in a final volume of 100 l/well) were plated in triplicate in flatbottomed Nunclon Õ 96-Well MicroWell Õ plates (Nunclon, Life Technologies, UK) and cultured at 378C, 5% CO 2 and 95% air in a humidified atmosphere. Con-A 10 g/ml (dose established by preliminary experiments) was used to stimulate the cells in the presence of different concentrations of hydrocortisone (10
À6 , 10 À5 , 10 À4 M). Hydrocortisone was always prepared fresh at the start of each experiment.
After 72 h of culture, 100 l of Cell Titer-Glo reagent was added to each well according to manufacturer's instructions, and inhibitory effects of hydrocortisone were determined on cell proliferation/viability (Promega G7570, Southampton, UK) by measuring the relative light units (RLU) using a MLX microtitre plate luminometer (Dynex Technologies, Chantilly, VA, USA). The mean RLU of triplicate of each sample were calculated. The percentage inhibition of cell proliferation by hydrocortisone was calculated using the following formula:
where, x, RLU in hydrocortisone and Con-A; n, RLU in TCM alone; y, RLU in con-A alone. The IC 50 of hydrocortisone on cell proliferation was determined from the dose-response curves. The IC 50 was defined as the concentration of hydrocortisone that caused a 50% inhibition of cell proliferation; by this calculation the variations in con-A-induced proliferation that occur between individuals and in the same individual were compensated for. Subjects with an IC 50 of >10 À6 M were considered to be SR resistant as previously described [2] .
Determination of CR isoform expression
Cell culture. PBMCs, collected as described above, were re-suspended at a concentration of 1 Â 10 6 cells/ml in RPMI 1640 medium (GIBCO) containing 10% fetal bovine serum (GIBCO), 100 000 IU/l penicillin, and 100 mg/l streptomycin. Cells were pretreated with hydrocortisone (10 À6 M) or TCM for 5 min. and then incubated in the absence or presence of con-A (10 g/ml) for 1 h at 378C in 5% CO 2 . Subsequently, cells were centrifuged at 400 g/15 min at 48C, supernatant was discarded and RNA extracted as described below.
RNA isolation and cDNA synthesis. Total RNA from PBMCs were isolated using RNA STAT-60 Reagent (Biogenesis, Poole, UK) according to manufacturer's instructions. After washing, the mRNA was air dried and suspended in DEPC-treated water after which the optical density (OD) 260/280 was determined (>1.7), and used for calculation of the concentration. cDNA was prepared using PROMEGA A3500 kit (Southampton, UK). 1.0 g of sample RNA was denatured for 10 min at 708C, and then mixed with a buffer containing 10 mM Tris-HCl, pH 9.0, 50 mM KCl, 0.1% Triton X-100, 5 mM MgCl 2 , 1 mM each dGTP, dATP, dTTP, dCTP, 0.5 g oligo dT primer, 20 U RNase inhibitor, 15 U AMV reverse transcriptase, in a final volume of 20 l. This mixture was incubated for 15 min at 428C, heated at 998C for 5 min, and then incubated at 0-58C for 5 min.
Quantitative real time PCR (qRT-PCR). For qRT-PCR
analysis, TaqMan technology was applied, according to the manufacturer's instructions. Taqman qRT-PCR involves the continuous detection of newly formed amplicons during PCR cycling, using a forward primer, a reverse primer and a FAM-TAMRA probe, which anneals between the two other primers. qRT-PCR was performed in triplicate for each sample using the ABI PRISM 7900HT Sequence Detector (Perkin-Elmer Applied Biosystems) and the TaqMan EZ RT-PCR Core Reagents Kit (Perkin-Elmer Applied Biosystems). The qRT-PCR was performed for CR, CR and -actin as a control housekeeping gene. Sequences for forward and reverse oligonucleotide primers as well as the TaqMan probes used in this study are detailed in Table 2 . These oligonucleotides were designed using Primer Express software (PE-Applied Biosystems, Warrington, UK) and primers spanning intron sequences were selected to differentiate amplification from genomic DNA. All primers and probes were synthesized by Sigma (UK). The qRT-PCR primers and probes are shown in Table 2 .
Before application of Taqman qRT-PCR to determine CR and CR ratio, the capacity of the technique to detect differences in ratios of synthesized RNAs was validated. Amplicons presenting parts of exon 9 or exon 9 were generated from HeLaS 3 cDNA, mixed in different ratios and analysed by Taqman qRT-PCR. Cycle conditions were as follows: initial denaturizing at 958C for 10 min, 50 cycles of 958C for 15 s, 608C for 60 s, elongating at 728C for 60 s and one final elongation step of 5 min at 728C. Tenfold serial dilutions (spanning four orders of magnitude) of HeLa S3 cDNA of known concentrations were used to construct standard curves of cycle threshold (Ct) values for CR, CR and -actin.
Analysis of cellular expression of CR protein isoforms by flow cytometry
PBMCs were isolated from blood collected between 10:00 and 11:00 A.M. from RA patients as described above. Cells were stained for CR and CR using a modification of the flowcytometry method for intracellular proteins as previously described [26] and analysed by fluorescent activated cell sorter (FACS). HeLaS3 cells, which over-express CR, were used as a positive test control.
Antibodies for immunofluorescence staining. The irrelevant non-specific Simultest TM IgG control was a mixture of FITC-and PE-conjugated mouse antibody isotype IgG2a (Becton Dickinson, San Jose, California). The first layer antibodies were an affinity purified protein rabbit polyclonal antibody GR(P-20) (Autogen Bioclear UK Ltd, Devizes, UK) and/or GCR-PA3-514 (Affinity Bioreagents, Golden, USA) directed against CR and CR, respectively, as indicated. The affinity purified protein antibodies only bind to their target protein molecules. The second antibody was FITC-conjugated polyclonal goat anti-rabbit (GAR) (BD Biosciences, San Diego, CA, USA). In order to reduce non-specific binding to other intracellular proteins, GAR-FITC was serially pre-adsorbed as previously described [25] .
PBMCs isolated by density gradient centrifugation were washed twice with a wash solution [WS; phosphate-buffered saline (PBS) containing 0.01% azide and 0.1% bovine serum albumin (BSA)] by resuspension of the cell pellet in the solution and centrifugation at 500 g. Cells were then fixed by incubation for 10 min on ice, in 1 ml of a 1% paraformaldehyde solution in PBS containing 0.1% BSA and then washed twice. Cells were then placed in each tube and treated as detailed below.
Permeabilization was performed with 1.2% n-octyl glucoside (NOG) for 7.5 min at 48C. After permeabilization the cells were washed twice with WS and then stained. Cells were incubated with 20% normal human serum (NHS) for 10 min, washed twice. The first antibody was added (5 l) and cells were incubated at 258C for 20 min then washed twice. The second antibody preadsorbed GAR-FITC (5 l) was added and cells were incubated at 258C for 20 min then washed twice again with WS. Normal mouse serum (10 l) was added, and cells were incubated at 258C for 20 min then washed twice before adding the third final layer of antibodies. Finally, cells were washed twice and then resuspended in 500 l of PBS/1% paraformaldehyde/0.1% BSA solution before FACS analysis. Flow-cytometric analysis was carried out using a Becton Dickinson FACscan Calibur and results were analysed using WinMDI V2.8 software. The cells were gated for forward and side scatter. The total number and percentage of positive PBMCs and the mean intensity of fluorescence (MIF) of CR and CR staining over background were determined.
Statistical analysis
The results are expressed as mean AE SEM. The results were analysed using SYSTAT 11 software. Non-parametric tests were used to analyse the differences between the observations seen in the SS and SR RA subjects with Wilcoxon matched-pair test for two-group comparisons with exact, two-tailed significance levels and analysis of variance. A value of P 0.05 was considered to indicate statistical significance.
Results
Steroid sensitivity status of patients. There were no significant differences in the degree of inflammation between the two subgroups of patients as measured by the levels of ESR, CRP and number of active joints ( Table 1 ). The distribution of RF seropositivity status, gender ratios and disease duration were similar between the SS and SR RA subgroups. Subjects were subdivided using the hydrocortisone IC 50 of 10 À6 M into SS and SR subgroups as previously described [2] . The mean dose-response curves of the subgroups are shown in Fig. 1 . As can be seen, there are significant differences in the percentage inhibition of cell proliferation at each dose point between the SS and SR subjects.
Levels of CR isoform mRNA expression in PBMCs as determined by qRT-PCR. Taqman RT-PCR was used to quantitate levels of expression of the receptor isoforms. All PCR products were evaluated on the basis of the individual -actin housekeeping gene expression. For CR and CR isoform expression, cDNA samples from PBMCs from RA patients were analysed. The expression of mRNA levels of CR and CR isoforms at basal and following stimulation with con-A, in the absence or presence of hydrocortisone were compared between the SS and SR subgroups (Fig. 2) . The level of CR mRNA expression was the same in both subgroups. A trend towards higher basal expression of CR mRNA in PBMCs was observed in SR RA patients than in the SS RA subgroup. Con-A stimulation without or with hydrocortisone caused a significant increase in the expression of the CR isoform in SR RA patients compared with the SS RA subjects (P < 0.05 and P < 0.02, respectively). Con-A stimulation did not cause an increase in CR mRNA in the SS RA subgroup and hydrocortisone caused a 14.5% downward trend inhibition in expression (Fig. 2B) . In contrast, con-A enhanced CR isoform mRNA expression by 20%, in the SR RA patients, which was not inhibited at all by hydrocortisone (Fig. 2B) . However, the differences in the relative over-expression of CR in SR RA patients become more highly significant when one looks at the CR/CR ratio of mRNA expression (Fig. 2C) . The basal CR/CR ratio shows a trend towards higher levels in PBMCs from SR RA subjects than in SS RA patients. Significant changes are observed following stimulation of PBMCs in vitro with con-A alone and treatment of con-A-stimulated PBMCs with hydrocortisone with a significantly higher CR/CR ratio in SR RA patients (P 0.01 and P 0.01, respectively). Thus, overall, the qRT-PCR data suggest that CR mRNA is over-expressed in SR RA patients.
Protein expression levels of the CR isoforms in PBMCs. Since overexpression of CR protein has been shown to reduce the effects of CS, we analysed the protein expression of the CR isoforms using flow cytometry. Fig. 3 (panels A-D) shows representative immunocytofluorographic data from an SR and SS RA subject. As can be seen, the percentage of PBMCs expressing CR protein is higher in SR RA subjects. The results from a group of SS and SR patients are summarized in Fig. 4 (panels A  and B) . For the CR isoform, there were no significant differences between the SS and SR RA patients (Fig. 4, panels A and B) . However, the percentage of PBMCs staining for CR was significantly lower in the SS RA group (P < 0.001). The MIF of CR staining was also higher in the SR RA subgroup of patients than in the SS subjects (P < 0.001). These data support the qRT-PCR observations in SR RA patients that CR is relatively over-expressed in PBMCs from RA patients who are SR as defined by the in vitro CS bioassay.
Discussion
A number of molecular mechanisms may be involved in SR and this may be related to perturbations of the cellular pathways used by CSs to exert their biological effects [27, 28] . One of these relates to perturbations of the CR isoform expression. CSs mediate their genomic effects via the CR receptor. A number of cell line transfection experiments have shown that the relative over-expression of the CR isoform induces a state of reduced sensitivity to the inhibitory effects of CS on gene expression [18] [19] [20] . Using qRT-PCR analysis and flow cytometry, we show for the first time enhanced CR mRNA and protein expression in PBMCs from SR RA patients when compared with the SS RA patient subgroup. We also demonstrate that con-A stimulation of PBMCs from SR RA patients enhances overexpression of CR mRNA, which is not inhibited by hydrocortisone treatment. This observation is of pathophysiological relevance to the molecular basis of the SR phenomenon, since such a relative increase in CR expression during cell activation may occur during inflammation and could potentially contribute to a reduced state of responsiveness to the biological effects of CS therapy.
Our observations in RA patients at the mRNA level were also reflected at the protein level in PBMCs. Our flow-cytometry data are highly significant since the CR isoform does not undergo ligand-dependent down-regulation and consequently has a much longer half-life than that of CR [29] . Thus, even low levels of CR protein may achieve a significant dominant negative effect on the activity of CR isoform [29] . Hence, even the small increases in CR mRNA expression such as observed at the basal level in the SR RA patients, may translate into significant protein expression and the associated biological effects. Minimal perturbations of the CR/CR mRNA ratio, may lead to prolonged and enhanced CR mediated inhibitory effects at the protein level. Our observations at the protein level in SR RA patients, are similar to the in vivo observations of Sousa et al. [30] and Hamid et al. [31] in SR asthmatic patients. Using fluorescence microscopy, Hamid et al. [31] examined broncho-alveolar lavage cell cytospins from SS and SR asthmatic patients stained by immunohistochemistry for the expression of CR. broncho-alveolar lavage cell preparations from SR asthmatic patients had a significantly higher expression of CR. Sousa et al.
[30] measured the CR and CR immunoreactive cells in skin biopsies from tuberculin-induced skin lesions in SS and SR asthmatic patients. The number of cells expressing CR was higher in skin lesions biopsies of SR asthmatic patients [30] . Similar findings have been seen in PBMCs from patients with ulcerative colitis by Honda et al. [32] . They used real timepolymerase chain reaction (RT-PCR) analysis to detect CR and CR in PBMCs from ulcerative colitis patients and assessed the potential of detecting CR as a predictor of the likelihood of responding to CS therapy in patients whose disease flared [32] . CR mRNA was detected in a significantly higher percentage of patients who failed to respond adequately to CS therapy.
The mechanisms responsible for the enhanced expression of CR in SR RA patients are currently unknown. Alternative splicing of the CR pre-mRNA gives rise to the homologous CR mRNA. Knowing the exact mechanisms that regulate alternative splicing of CR pre-mRNA could be exploited as a therapeutic application. Such research is currently being done in Duchenne muscular dystrophy to produce a different isoform of dystophin [33] .
The physiological and pathophysiological role of the CR isoform is controversial. Co-transfection experiments with human CR and CR expression vectors and GRE-containing reporter plasmid to COS cells by three independent groups have shown that CR over-expression inhibits GRE-containing gene expression [18] [19] [20] . Others have, however, provided conflicting data [21] [22] 34] . The latter may represent a limitation of cell line co-transfection experiments. Human neutrophils are less sensitive than T cells to the apoptotic effects induced by CS and this may explain in part the observation that CSs are less effective at resolving neutrophil-associated inflammation [35] . This may be a consequence of the higher constitutive expression of CR by neutrophils in comparison with T cells [36] . Mouse neutrophils do not express CR and are very sensitive to CS-induced apoptosis [37] . Transfection of mouse neutrophils with a pRSh CR expression vector results in a significant reduction of dexamethasone-induced neutrophil apoptosis [36] . This is the closest indirect ex-vivo experimental evidence supporting the view that the over-expression of CR in SR RA patients we have observed in our studies has direct pathophysiological relevance to the phenomenon of SR. More recently, Charmandari et al. [37] have studied the mechanisms underlying the dominant negative effects of the CR isoform on steroid receptor coactivators [38] . They showed that CR suppressed the transcriptional activity of both activation of function (AF)-1 and AF-2 of CR by binding to the p160 coactivators and the CR interacting protein 1 (CRIP1) [38] . This finding supports our hypothesis that in SR RA patients the enhanced CR expression is of pathophysiological relevance to the SR phenomenon. RA patients have reduced numbers of CRs on their lymphocytes but this does not result in reduced biological effects of CS per se [39] . It therefore remains to be determined whether there are differences in post-receptor mechanisms in the SS and SR RA patients. We are currently investigating this possibility.
It has been suggested that methotrexate may increase CR expression and thus potentially increase susceptibility to CS inhibition. All the SS and SR RA patients were on methotrexate and thus the differences in the expression of CR isoforms are not secondary to methotrexate. Furthermore, the duration of RA disease, levels of inflammation as measured by the levels of ESR, CRP and number of active joints were not significantly different between the SS and SR subjects.
Conclusions
In conclusion, we show for the first time that the CR isoform is over-expressed in SR RA patients at both the mRNA and protein levels. Furthermore, hydrocortisone fails to inhibit the con-A induced increase in CR mRNA. This over-expression of CR by PBMCs may in part explain the reduced responsiveness to CS therapy observed in these patients. 
